Prognostic Factors in Patients Diagnosed with High Grade Glioma Managed with Radiotherapy: Experience at the Federico Gómez Children's Hospital of Mexico

2019 ◽  
Vol 16 (1) ◽  
Author(s):  
María Fátima Chilaca-Rosas ◽  
Heynar de Jesús Pérez-Villanueva ◽  
Noé Trinidad-Hernández ◽  
Juan Carlos Heredia-Gutiérrez ◽  
Héctor Urueta-Cuéllar
Keyword(s):  
Prognostic Factors ◽  
High Grade Glioma ◽  
High Grade ◽  
Children's Hospital ◽  
Children’S Hospital

Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience

2020 ◽  
Vol 148 (3) ◽  
pp. 607-617
Author(s):  
Erin E. Crotty ◽  
Sarah E. S. Leary ◽  
J. Russell Geyer ◽  
James M. Olson ◽  
Nathan E. Millard ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Children's Hospital ◽  
Hospital Experience ◽  
Children’S Hospital

scholarly journals EP-1219 Prognostic factors of salvage stereotactic radiotherapy for recurrent high-grade glioma.

2019 ◽  
Vol 133 ◽  
pp. S673-S674
Author(s):  
K. Takehana ◽  
M. Uto ◽  
K. Ogura ◽  
Y. Arakawa ◽  
Y. Mineharu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Stereotactic Radiotherapy ◽  
High Grade Glioma ◽  
High Grade

scholarly journals Characteristics and prognostic factors of age-stratified high-grade intracranial glioma patients: A population-based analysis

2019 ◽  
Author(s):  
Yun Sun ◽  
Zhi-yong Xiong ◽  
Peng-fei Yan ◽  
Liang-lei Jiang ◽  
Chuan-sheng Nie ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Survival Data ◽  
Age Groups ◽  
High Grade Glioma ◽  
Population Based ◽  
High Grade ◽  
Treatment Protocols ◽  
Cox Models ◽  
Cause Specific Survival

We evaluated characteristics and different prognostic factors for survival in age-stratified high-grade glioma in a US cohort. Eligible patients were identified in the Surveillance, Epidemiology, and End Results (SEER) registries and stratified into 3 age groups: 20-39 years old (1,043 patients), 40-59 years old (4,503 patients), and >60 years old (5,045 patients). Overall and cancer-related survival data were obtained. Cox models were built to analyze the outcomes and risk factors. It showed that race was a prognostic factor for survival in patients 40 to 59 years old and in patients ≥60 years old. Partial resection was associated with lower overall survival and cause-specific survival in all age groups (overall survival: 20-39 yr: HR=6.41; 40-59 yr: HR=4.84; >60 yr: HR=5.06; cause-specific survival: 20-39 yr: HR=5.87; 40-59 yr: HR=4.01; >60 yr: HR=3.36). The study highlights that, while some prognostic factors are universal, others are age-dependent. The effectiveness of treatment approaches differs for patients in different age groups. Results of this study may help to develop personalized treatment protocols for glioma patients of different ages.

Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience

2020 ◽  
pp. 107815522092068
Author(s):  
Ozkan Alan ◽  
Tugba Akin Telli ◽  
Tugba Basoglu Tuylu ◽  
Rukiye Arikan ◽  
Nazım Can Demircan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Systemic Treatment ◽  
Progression Free Survival ◽  
High Grade Glioma ◽  
Idh1 Mutation ◽  
High Grade ◽  
Free Survival ◽  
Median Progression Free Survival ◽  
Ecog Ps

Purpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17–77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1–68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.

Prognostic Factors for Post-Thrombotic Syndrome in Children with Limb DVT: A Bi-Institutional Cohort Study

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3401-3401
Author(s):  
Courtney A. Lyle ◽  
Elizabeth Gibson ◽  
Amy Lovejoy ◽  
Neil A Goldenberg
Keyword(s):  
Cohort Study ◽  
Prognostic Factors ◽  
Therapeutic Interventions ◽  
Significant Prognostic Factor ◽  
Advisory Committees ◽  
Children's Hospital ◽  
Post Thrombotic Syndrome ◽  
Glycoprotein I ◽  
Children’S Hospital ◽  
Clinically Significant

Abstract Abstract 3401 Background: Early identification of children with deep venous thrombosis (DVT) of the limb, whoare at heightened risk for post-thrombotic syndrome (PTS), is important in order to evaluate therapeutic interventions aimed at decreasing the risk and severity of PTS. Objective: We sought to evaluate prognostic factors for PTS in children following DVT of the limbs. Methods: In this bi-institutional mixed cohort study with prospective ascertainment of PTS using a validated pediatric instrument, we collected data on patient/thrombus characteristics, thrombophilia testing results, and outcomes in children (<21 years at event) diagnosed with acute limb DVT at Rady Children's Hospital of San Diego and Children's Hospital Colorado. Results: Median age at presentation was 13 years (range, 0–18 years). Cumulative incidence (i.e., risk of PTS) was 23%, at a median follow-up duration of 33 months (range: 13.2–65 months). The presence of a lupus anticoagulant by dilute Russell Viper venom time (dRVVT) testing within two weeks of DVT diagnosis was associated with markedly increased odds of developing clinically-significant PTS (OR 16.8, 95%CI (1.60–176.2); P=0.02). The presence of an infectious or inflammatory condition at DVT presentation was neither associated with PTS risk nor dRVVT positivity. Conclusions: An acutely positive dRVVT following diagnosis of limb DVT appears to be a significant prognostic factor for development of clinically significant PTS in children. Larger collaborative cohort studies are required to substantiate these findings, evaluate other prognostic factors, and determine whether the present association is modulated by persistent dRVVT positivity or beta-2-glycoprotein-I dependence. Disclosures: Goldenberg: Eisai Inc: Research Funding; Pfizer Inc: Membership on an entity's Board of Directors or advisory committees; CPC Clinical Research: Consultancy.

Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis

2011 ◽  
Vol 154 (2) ◽  
pp. 211-222 ◽  
Author(s):  
Gregorio Catalán-Uribarrena ◽  
Gaizka Bilbao-Barandica ◽  
Iñigo Pomposo-Gaztelu ◽  
José Undabeitia-Huertas ◽  
Edurne Ruiz de Gopegui-Ruiz ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Prospective Cohort ◽  
High Grade Glioma ◽  
High Grade ◽  
Intention To Treat ◽  
Carmustine Wafers

Prognostic factors and survival study in high-grade glioma in the elderly

2016 ◽  
Vol 30 (3) ◽  
pp. 330-336 ◽  
Author(s):  
Sayoa Álvarez de Eulate-Beramendi ◽  
Marco Antonio Álvarez-Vega ◽  
Milagros Balbin ◽  
Ana Sanchez-Pitiot ◽  
Aitana Vallina-Alvarez ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
High Grade Glioma ◽  
The Elderly ◽  
High Grade ◽  
Survival Study

scholarly journals Salvage Radiosurgery for Selected Patients with Recurrent Malignant Gliomas

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Miguel Martínez-Carrillo ◽  
Isabel Tovar-Martín ◽  
Mercedes Zurita-Herrera ◽  
Rosario Del Moral-Ávila ◽  
Rosario Guerrero-Tejada ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Stereotactic Radiosurgery ◽  
Anaplastic Astrocytoma ◽  
Cox Regression ◽  
Malignant Gliomas ◽  
High Grade Glioma ◽  
Initial Diagnosis ◽  
Karnofsky Performance Score ◽  
High Grade ◽  
Effective Treatment Option

Purpose. To analyse the survival after salvage radiosurgery and to identify prognostic factors.Methods. We retrospectively reviewed 87 consecutive patients, with recurrent high-grade glioma, that underwent stereotactic radiosurgery between 1997 and 2010. We evaluated the survival after initial diagnosis and after reirradiation. The prognostic factors were analysed by bivariate and multivariate Cox regression model.Results. The median age was 48 years old. The primary histology included anaplastic astrocytoma (47%) and glioblastoma (53%). A margin dose of 18 Gy was administered in the majority of cases (74%). The median survival after initial diagnosis was 21 months (39 months for anaplastic astrocytoma and 18.5 months for glioblastoma) and after reirradiation it was 10 months (17 months for anaplastic astrocytoma and 7.5 months for glioblastoma). In the bivariate analyses, the prognostic factors significantly associated with survival after reirradiation were age, tumour and treatment volume at recurrence, recursive partitioning analyses classification, Karnofsky performance score, histology, and margin to the planning target volume. Only the last four showed significant association in the multivariate analyses.Conclusion. stereotactic radiosurgery is a safe and may be an effective treatment option for selected patients diagnosed with recurrent high-grade glioma. The identified prognostic factors could help individualise the treatment.

Sign in / Sign up

Export Citation Format

Share Document